Author
Dr Chinedu Madichie
Service Line
GxP Audits & Inspection Readiness
Executive Brief
In global clinical trials, outsourcing investigational medicinal product (IMP) storage, packaging interfaces, order fulfilment, and transport to third-party depots and couriers is standard practice. However, European Medicines Agency (EMA) and International Council for Harmonisation (ICH) guidelines dictate that outsourcing operational tasks does not transfer regulatory accountability. Sponsors remain responsible for IMP quality, safety, chain of custody, and treatment blinding until formal acceptance at the trial site.
At BethAri Limited, our quality risk practice observes that many life science sponsors execute vendor requalification as a static, calendar-driven formality. This legacy approach creates systemic vulnerability, exposing sponsors to regulatory inspection deficiencies and distribution failures. This whitepaper synthesises regulatory mandates, inspection findings, and operational benchmarks to present BethAri Limited’s integrated, risk-based requalification framework. By shifting from rigid calendar audits to dynamic, performance-informed lifecycle oversight, BethAri Limited enables pharmaceutical and biotechnology clients to protect participant safety, secure trial continuity, and optimize oversight resources.
The Market Challenge
Modern clinical trial supply chains are intricate and geographically dispersed. Industry benchmarking data from a Tufts Center for the Study of Drug Development (Tufts CSDD) study by Lamberti et al. (2016) reveals that nearly three in five clinical trials (59%) depend on outsourced logistics service providers. Every external depot, transit hub, and courier hand-off represents a critical control point where temperature control, inventory traceability, container integrity, or treatment blinding can fail.
To navigate this operating environment, sponsors must align with two foundational standards. Good Distribution Practice (GDP)—codified in the EU via the European Commission’s 2013 GDP Guidelines (2013/C 343/01) derived from Directive 2001/83/EC—establishes quality standards for receiving, storing, handling, and transporting medicinal products. Requalification is defined as the documented, periodic or event-triggered reassessment of an approved vendor’s continuing operational competence, quality system maturity, and compliance.
For investigational products, the European Medicines Agency’s 2022 guideline on IMP handling and shipping dictates that sponsors apply applicable GDP principles to all IMP distribution activities. Crucially, the EMA mandates that sponsors maintain unbroken accountability for IMPs in transit until accepted by the site. Complementing this, the ICH E6(R3) Guideline for Good Clinical Practice (2025) establishes that while sponsors may delegate trial tasks to contract acceptors, ultimate responsibility remains strictly with the sponsor. Sponsors must maintain continuous, documented oversight of transferred functions, including secondary subcontracting arrangements. Direct-to-patient (DtP) shipping models, explicitly excluded from the 2022 EMA guideline scope, fall outside this framework.
Strategic Insights & Operational Evidence
Our analysis of global regulatory requirements, inspectorate findings, and operational benchmarks highlights four core pillars governing clinical supply vendor oversight: continuous accountability, risk-proportional scheduling, quality system integrity, and rigorous subcontracting control.
Regulatory Requirements & Risk-Proportional Auditing
European Union GDP Guidelines (§7.2) mandate that contract givers evaluate contract acceptor competence prior to initiating outsourced services, following material operational modifications, and thereafter at a frequency determined by risk and activity nature. Contract givers must contractually retain audit rights at any time.
To operationalize audit frequency, ICH Q9(R1) Quality Risk Management (2023) establishes that quality review frequency and formality must align directly with risk level (§4.6). Annex II.1 of ICH Q9(R1) outlines illustrative risk factors for setting audit schedules: compliance history, risk management robustness, process and product complexity, therapeutic significance, quality defects and complaints, prior inspection/audit results, and major organizational or personnel changes.
ICH Q9(R1) notes that substantial service variability justifies enhanced review (§6.1c). Furthermore, ICH E6(R3) requires sponsors to tailor vendor oversight to trial complexity (§3.6.8), maintain access to provider SOPs and performance metrics (§3.9.5), and execute audits according to documented procedures defining audit scope, methodology, and frequency (§3.11.2.2). Notably, none of these regulatory documents prescribes fixed calendar re-audit intervals; ICH Q9(R1) explicitly notes that its Annex examples are illustrative rather than mandatory numerical mandates.
Audit Fatigue and In-Transit Vulnerabilities
Published literature on audit scheduling highlights operational limitations of traditional time-driven models. Work by Rönninger and Holmes (2009) describes legacy calendar-driven cycles (such as mandatory 1-to-5-year re-audits), noting periodic audits capture only a single point-in-time snapshot. They report major pharmaceutical suppliers frequently experience audit fatigue, receiving over one audit per working day, leading some to decline routine audits. Rönninger and Holmes propose an ICH Q9-aligned model integrating compliance metrics to adjust audit depth and frequency. Vargo et al. (2014) extend this risk-based auditing logic across manufacturing and distribution networks. Evaluated abstracts indicate that while risk-based scheduling is logically sound, published literature lacks controlled comparative trials validating specific numerical re-audit intervals.
Empirical inspection data demonstrates where distribution controls fail. A UK Medicines and Healthcare products Regulatory Agency (MHRA) review of 148 GDP inspections in 2016 (Brown et al., 2017) identified recurring critical deficiencies: failure to audit contract acceptors, unreviewed subcontracting terms, expired technical agreements, uncalibrated temperature devices, inability to demonstrate end-to-end journey temperature control, and signing off CAPA records while corrective actions remained outstanding.
MHRA practitioner guidance (2014/2024) indicates inspectors focus on stock management, storage conditions, temperature monitoring, returns, purchasing validity, and transport arrangements. In clinical logistics, the Tufts CSDD study by Lamberti et al. (2016) found temperature excursions occurred most frequently during customs clearance or upon arrival at trial sites. Resolving product disposition following an excursion required an average of 57 hours (ranging from 6 to 114 hours). Although based on a sample of 12 companies and 17 respondents, these findings illustrate critical operational friction points.
IMP Distribution Controls
The EMA (2022) IMP-shipping guideline defines explicit distribution requirements: IMPs must remain under sponsor release control prior to dispatch; transport must follow storage conditions in the Product Specification File; critical equipment must be qualified; temperature records must be reviewed upon delivery; shipping deviations must undergo formal investigation with CAPA effectiveness monitored; inventory systems must maintain full traceability; and site-to-site IMP transfers must remain exceptional and SOP-governed. In addition, ICH E6(R3) requires that transport arrangements preserve treatment blinding (Principle 11.4).
Business Advisory & Client Implications
Because regulatory bodies mandate risk-proportional audit frequencies without prescribing universal calendar intervals, a sponsor’s requalification schedule is defensible only when supported by a documented risk rationale. ICH Q9(R1) warns that ill-defined risk questions, subjective scoring scales, or internal resource constraints compromise quality risk management integrity (§5.1, §5.3). At BethAri Limited, we advise client leadership teams to avoid relying on subjective impressions, establishing instead a quantitative risk profile.
The BethAri Seven-Factor Risk Framework
Drawing from regulatory guidelines and operational evidence, BethAri Limited has synthesized an evaluation model that categorises vendor risk into inherent service complexity and post-approval performance history across seven criteria:
- Product Sensitivity: IMP stability margins, cold-chain or cryogenic requirements, and specialized storage conditions.
- Activity Criticality & Complexity: Multi-depot networks, custom packaging interfaces, route hand-offs, and customs clearance complexity.
- Performance Trend: Frequency of temperature excursions, shipping delays, deviation rates, alarm responses, and CAPA timeliness.
- Compliance & Audit History: Historical audit findings, regulatory inspection outcomes, licence currency, and CAPA closure quality.
- Organizational & Operational Change: Material changes in vendor ownership, key personnel, storage facilities, IT infrastructure, or transport lanes.
- Subcontracting Controls: Oversight rigor regarding secondary couriers, regional depots, or third-party logistics (3PL) subcontractors.
- Trial Exposure: Scale of trial participant exposure, therapeutic criticality of the IMP, and clinical development phase.
Where high risk or elevated uncertainty exists—such as onboarding a new vendor or deploying novel transport routes—establishing shorter initial re-audit intervals or early follow-up visits represents the necessary risk-mitigation strategy. Extending re-audit intervals is defensible only for lower-risk vendors demonstrating verified operational stability under continuous routine monitoring.
Audit Execution & Noncompliance Governance
ICH E6(R3) recognizes on-site and remote auditing approaches within documented audit procedures. BethAri Limited’s advisory practice notes that while remote reviews efficiently evaluate documentation, SOPs, quality metrics, and CAPA records, an on-site audit element remains essential whenever physical storage controls, cold-chain infrastructure, or warehouse handling represent primary risk drivers. Furthermore, vendor requalification must culminate in a definitive governance decision—confirming full approval, conditional approval with remediation, elevated monitoring, or contract termination in cases of persistent significant noncompliance.
Our Core Framework & Actionable Takeaways
To help client organizations operationalize regulatory expectations, BethAri Limited deploys a structured Vendor Requalification Framework. We advise corporate sponsors to implement six actionable steps:
- Establish Procedural Governance & Risk Methodology: Draft an SOP defining risk assessment criteria, scoring mechanisms, risk tiers, maximum re-audit intervals, and mandatory event-trigger rules prior to evaluating vendor performance.
- Conduct Baseline & Seven-Factor Risk Ratings: Evaluate active clinical supply vendors across BethAri’s seven risk criteria. Verify baseline legal authorizations, quality agreements, facility qualifications, and personnel training prior to IMP dispatch.
- Define Tiered Maximum Intervals with Local Rationales: Establish risk-tiered maximum re-audit intervals and document clear corporate rationales for each tier, recognizing that regulations prescribe no universal calendar frequencies.
- Institute Dynamic Event-Triggered Requalification: Implement procedural rules that immediately trigger an out-of-sequence audit upon key risk events, including facility or ownership changes, unapproved subcontractors, severe temperature excursions, critical audit findings, or data-integrity failures.
- Execute Data-Driven Pre-Audit Reviews & On-Site Operational Tracing: Prior to auditing, analyze KPIs, excursion logs, deviation trends, open CAPAs, change controls, and quality agreement currency. During audits, inspect physical operations directly—verifying storage compliance per the Product Specification File, equipment calibration, transport validation, blinding maintenance, and subcontractor oversight—by performing end-to-end tracing of representative live shipments from dispatch through site receipt, return, and disposition.
- Verify CAPA Effectiveness & Close Governance Loops: Mandate that CAPA files undergo formal verification of operational effectiveness rather than administrative sign-off. Utilize audit outcomes and CAPA effectiveness data to update vendor risk profiles, adjust quality agreements, and record explicit re-audit timing decisions. Condition interval extensions strictly on verified, stable performance data.
Strategic Outlook & Emerging Horizons
The evidence base governing clinical supply chain oversight continues to evolve. Current regulatory expectations provide robust principles but lack comparative empirical studies establishing which specific re-audit intervals yield optimal distribution outcomes. Published scheduling literature remains limited to expert models evaluated from abstracts, while empirical inspection statistics reflect UK wholesale distribution data from 2016 and clinical logistics benchmarks from 2014–2015. Comparative research regarding the relative effectiveness of remote versus on-site audits remains unexamined in published peer-reviewed literature.
Looking ahead, life science companies face expanding supply chain complexities, including advanced therapeutic medicinal products (ATMPs) with hyper-sensitive cold-chain requirements, real-time temperature tracking, and evolving global regulatory scrutiny. Industry practice will benefit significantly from future empirical research analyzing vendor deviation rates across risk tiers and inspectorate deficiency trends specific to clinical supply logistics.
How We Help
Requalifying clinical supply vendors under GDP and GCP frameworks is a critical lifecycle risk management discipline. Authoritative guidelines from the EU and ICH confirm three immutable principles: sponsor accountability is non-transferable, oversight must be proportionate to risk, and audit frequencies must dynamically adapt to emerging performance signals and operational changes.
BethAri Limited serves as the strategic partner for pharmaceutical, biotechnology, and medical device sponsors seeking to build resilient, compliant, and risk-intelligent supply chain oversight programs. Our Life Sciences Quality & Risk Advisory practice delivers support across three core capability areas:
- Framework & SOP Architecture: We design customized, regulatory-compliant vendor risk rating models, SOPs, and governance structures tailored to client trial portfolios.
- Audit Execution & Live Tracing: Our certified auditors conduct on-site and remote vendor requalification audits, executing live end-to-end shipment tracing and cold-chain verifications.
- CAPA Remediation & Risk Intelligence: We assist sponsors in evaluating CAPA effectiveness, resolving temperature excursion investigations, and embedding continuous performance monitoring systems.
By partnering with BethAri Limited, life science organizations transform vendor requalification from an administrative burden into a competitive advantage—ensuring continuous regulatory compliance, protecting product integrity, and safeguarding trial participants worldwide.
Get in touch
If you would like to discuss how these issues apply to your organisation, BethAri would be glad to talk. Contact us to start the conversation.